Novartis invests $170 million for ex-U.S. rights to Luxturna

Swiss-based Novartis Pharmaceuticals has acquired rights to commercialize Luxturna—Spark Therapeutics’ gene therapy for inherited retinal dystrophy—outside of the United States.

https://www.aao.org/headline/novartis-invests-170-million-ex-u-s-rights-to-luxt

Comments

Popular posts from this blog

The Hidden Perils of Eye Rubbing

Save Your Vision at All Stages in Life

Zeaxanthin and Lutein Save the Eyes and Improve Brain Circulation